Clinical Trials(ICH-GCP Compliant)
Evitar™ (TTX 333)
Unprecedented Efficacy Data
Problem
Current products ineffective at preventing incidence of adhesions in laparoscopic surgeries.
Study Design
•Double-blind, placebo controlled randomized trial PLUS three blinded independent medical reviewers
•25%-33% of patients undergoing laparoscopy myomectomies develop adhesions (Hermann & Widle 2015)
Results
•89.8% reduction in risk of developing ANY adhesions compared to those who received placebo
•At least a 5x improvement over placebo; p=0.0456
•No safety signals or AE’s or SAE’s
Opportunity
EvitarTM is an effective and promising safe drug to PREVENT adhesion formation after laparoscopy surgery
Figure 1: Percentage of patients developing any adhesions
.png)
Table 1: Number of patients developing adhesions placebo vs Evitar treatment
